Skin and Joints Podcast

It Takes Two to TYK-2 PART 1: Zooming in on Deucravacitinib and What It Means for Your Patients with PsO

Episode Summary

🎧 TYK-TOK we’re ready to rock. 🎙️🎙️ The Skin and Joints Podcast Team is starting 2023 off strong with dermatologist dynamic duo Dr.Chih-Ho Hong and Dr.Irina Turchin who respectively lend their real world perspectives on a brand new oral therapy for our patients with moderate to severe psoriasis. 🛎️ Deucravacitinib is finally here! 🧵How does it compare with other biologics and non-biologic treatments? 🫳 How effective is it for patients specifically with moderate to severe scalp, nail and palmoplantar psoriasis? Episode Learning Objectives Apply current evidence as well as shared decision-making to individualize therapy decisions for patients with moderate to severe plaque psoriasis; specifically deucravacitinib, a novel oral TYK2 inhibitor (PART 1) Examine key real world considerations between TYK2 inhibitors with JAK inhibitors in terms of safety and tolerability (PART 1) Explore the correlations between responses on clinical and PRO measures in pooled data from POETYK PSO-1 and PSO-2 (PART 2) Evaluate the efficacy of deucravacitinib treatment in patients with moderate to severe scalp, nail, and palmoplantar psoriasis subgroup analyses pooled PSO-1 and PSO-2 data (PART 2) Episode supported by an IME Grant from BMS.

Episode Notes

🎧 🎉TYK-TOK we’re ready to rock.

🎙️🎙️ The Skin and Joints Podcast Team is starting 2023  off strong with dermatologist dynamic duo Dr.Chih-Ho Hong and Dr.Irina Turchin who respectively lend their real world perspectives on a brand new oral therapy for our patients with moderate to severe psoriasis.

🛎️ Deucravacitinib is finally here! And we're going to be looking at. some fresh new data that could change your clinical practice. 

🧵How does it compare with other biologics and non-biologic treatments?

🫳 How effective is it for patients specifically with moderate to severe scalp, nail and palmoplantar psoriasis? 

Episode Learning Objectives

• Apply current evidence as well as shared decision-making to individualize therapy decisions for patients with moderate to severe plaque psoriasis; specifically  deucravacitinib, a novel oral TYK2  inhibitor (PART 1)
• Examine key real world considerations between TYK2 inhibitors with JAK inhibitors in terms of safety and tolerability  (PART 1)
• Explore the correlations between responses on clinical and PRO measures in pooled data from POETYK PSO-1 and PSO-2 (PART 2)
• Evaluate the efficacy of deucravacitinib treatment in patients with moderate to severe scalp, nail, and palmoplantar psoriasis  subgroup analyses pooled PSO-1 and PSO-2 data  (PART 2)

Episode supported by an IME Grant from BMS.